Detalhe da pesquisa
1.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet
; 398(10308): 1344-1357, 2021 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34555333
2.
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Oncologist
; 19(2): 175-6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24457379
3.
Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.
Future Oncol
; 10(12): 1913-24, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25386810
4.
Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the Surgeon.
Ann Thorac Surg
; 115(6): 1544-1555, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36174774
5.
Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.
J Thorac Cardiovasc Surg
; 166(3): 655-666.e7, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36841745
6.
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
J Immunother Cancer
; 11(10)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903590
7.
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.
JTO Clin Res Rep
; 3(5): 100310, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35498382
8.
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC.
JTO Clin Res Rep
; 2(10): 100221, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34746882
9.
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer.
JTO Clin Res Rep
; 2(7): 100194, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590039
10.
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
Front Oncol
; 9: 132, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30915273
11.
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Clin Cancer Res
; 24(12): 2771-2779, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29563138
12.
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 82(4): 723-732, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30128950
13.
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
JAMA Oncol
; 4(11): 1583-1588, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29931076
14.
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
J Clin Oncol
; 36(14): 1412-1418, 2018 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29584545
15.
Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.
Nat Commun
; 9(1): 160, 2018 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29311577
16.
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Lung Cancer
; 106: 110-114, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28285684
17.
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
J Thorac Oncol
; 12(3): 446-457, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903463
18.
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.
Nat Commun
; 8(1): 1801, 2017 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180617
19.
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.
Clin Lung Cancer
; 17(2): 113-8.e1-2, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26498504
20.
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Cancer Discov
; 6(6): 601-11, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27102076